U.S. Markets close in 5 hrs 29 mins

POZEN's NDA for PA32540/PA8140 tablets accepted by FDA for review

POZEN's New Drug Application for PA32540/PA8140 has been accepted for review by the FDA. The FDA also indicated the review classification is Standard; therefore, the user fee goal date is January 24, 2014. Pending FDA review and approval, an indication is sought for PA tablets for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.